scholarly journals Modulation of the acute defence reaction by eplerenone prevents cardiac disease progression in viral myocarditis

2020 ◽  
Vol 7 (5) ◽  
pp. 2838-2852 ◽  
Author(s):  
Carsten Tschöpe ◽  
Sophie Van Linthout ◽  
Sebastian Jäger ◽  
Robert Arndt ◽  
Tobias Trippel ◽  
...  
Keyword(s):  
Disease Progression ◽  
Cardiac Disease ◽  
Viral Myocarditis ◽  
Defence Reaction

A SENSITIVE ELECTROCARDIOGRAPHIC SIGN IN MYOCARDITIS ASSOCIATED WITH VIRAL INFECTION

PEDIATRICS ◽  
1969 ◽  
Vol 43 (5) ◽  
pp. 846-851
Author(s):  
Ramon Rodriguez-Torres ◽  
Jer-Shoung Lin ◽  
Sumner Berkovich
Keyword(s):  
Viral Infection ◽  
Cardiac Disease ◽  
Viral Infections ◽  
Viral Myocarditis ◽  
Myocardial Disease ◽  
Normal Angle

The electrocardiographic signs used to diagnose myocardial disease are nonspecific. Therefore, it would seem to be of significance, that, in nine myocarditis children with proved viral infections (6 under 1 year of age), there was a constant electrical abnormality. Eight of the nine had abnormally wide spatial QRS-T angles. Recordings were made before onset of therapy and were repeated frequently during both the acute and convalescent phases of the illnesses. It was found that the return to a normal angle coincided with the disappearance of cardiac disease. Other findings were variable. The regularity with which an abnormal spatial QRS-T angle was detected in our children with viral myocarditis made this finding a valuable and dependable tool for detection and evaluation of their disease.

scholarly journals Unusual and severe peripartum cardiomyopathy: A case report

2021 ◽  
Vol 6 (2) ◽  
pp. 040-043
Author(s):  
B Lamanna ◽  
M Vinciguerra ◽  
FM Crupano ◽  
R Cicinelli ◽  
E Cicinelli ◽  
...  
Keyword(s):  
Cardiac Disease ◽  
Viral Myocarditis ◽  
Myocardial Damage ◽  
Maculopapular Rash ◽  
Peripartum Cardiomyopathy ◽  
Clinical Context ◽  
Reduced Ejection Fraction ◽  
Abnormal Immune Response ◽  
Long Term Prognosis

Peripartum cardiomyopathy (PPCM) is a relatively rare cardiac disease that manifests in the final stage of pregnancy and in the first months after delivery in women with no preexisting heart disease. Many etiological processes have been suggested: viral myocarditis, abnormal immune response to pregnancy, excessive prolactin excretion, prolonged tocolysis and a familiar predisposition to PPCM. Its diagnosis is often delayed because its symptoms, which include fatigue, dyspnea and palpitations are nonspecific. For this reason the diagnosis of PPCM is still made by exclusion of other etiologies. The long-term prognosis, once the acute phase is over, is a function of myocardial damage, this varies from complete functional recovery to chronic HF. The outcome of PPCM is highly variable with an alevated risk of fetomaternal morbidity and mortality. We report a serious case of a 40 years old female with biamniotic bicorionic twin pregnancy (PMA) who delivered by caesarean section and developed acute PPCM on post-operative. Symptoms occurred two hours after an intramuscular injection of two vials of methylergonovine the same day of cesarean delivery. These manifested in sudden tachypnoe, tachycardia and the appearance itchy maculopapular rash on her chest. On further evaluation, ECHO revealed cardiomegaly with reduced ejection fraction (< 15%). The case was successfully managed by a multidisciplinary team, using drugs like levosimendan and cabergoline, which rapresent emerging strategy in this clinical context.

scholarly journals ECG Beat based Cardiac Disease Progression Monitoring for Wearables

2020 ◽  
Author(s):  
Preethi Krishnan ◽  
bashir morshed ◽  
Viswanathan Rajagopalan
Keyword(s):  
Disease Progression ◽  
Real Time ◽  
Cardiac Disease ◽  
Recent Progress ◽  
Consumer Electronics ◽  
Disease Monitoring ◽  
Real Time Monitoring ◽  
Smart Health ◽  
Fast Acting

Real-time monitoring of cardiac disease progression using consumer electronics can be of immense benefit and realizable with the recent progress of wearables. This paper proposes a fast-acting personalized smart health wearable solution for cardiac disease monitoring using Electrocardiography (ECG). <br>

scholarly journals Cardiac Events After Radiation Therapy: Combined Analysis of Prospective Multicenter Trials for Locally Advanced Non–Small-Cell Lung Cancer

2017 ◽  
Vol 35 (13) ◽  
pp. 1395-1402 ◽  
Author(s):  
Robert T. Dess ◽  
Yilun Sun ◽  
Martha M. Matuszak ◽  
Grace Sun ◽  
Payal D. Soni ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Disease Progression ◽  
Cardiac Disease ◽  
Cardiac Event ◽  
Locally Advanced ◽  
Cardiac Events ◽  
Eligibility Criteria ◽  
Heart Dose ◽  
Grade 3 ◽  
Mean Heart Dose

Purpose Radiation therapy is a critical component in the care of patients with non–small-cell lung cancer (NSCLC), yet cardiac injury after treatment is a significant concern. Therefore, we wished to elucidate the incidence of cardiac events and their relationship to radiation dose to the heart. Patients and Materials Study eligibility criteria included patients with stage II to III NSCLC treated on one of four prospective radiation therapy trials at two centers from 2004 to 2013. All cardiac events were reviewed and graded per Common Terminology Criteria for Adverse Events (v4.03). The primary end point was the development of a grade ≥ 3 cardiac event. Results In all, 125 patients met eligibility criteria; median follow-up was 51 months for surviving patients. Median prescription dose was 70 Gy, 84% received concurrent chemotherapy, and 27% had pre-existing cardiac disease. Nineteen patients had a grade ≥ 3 cardiac event at a median of 11 months (interquartile range, 6 to 24 months), and 24-month cumulative incidence was 11% (95% CI, 5% to 16%). On multivariable analysis (MVA), pre-existing cardiac disease (hazard ratio [HR], 2.96; 95% CI, 1.07 to 8.21; P = .04) and mean heart dose (HR, 1.07/Gy; 95% CI, 1.02 to 1.13/Gy; P = .01) were significantly associated with grade ≥ 3 cardiac events. Analyzed as time-dependent variables on MVA analysis, both disease progression (HR, 2.15; 95% CI, 1.54 to 3.00) and grade ≥ 3 cardiac events (HR, 1.76; 95% CI, 1.04 to 2.99) were associated with decreased overall survival. However, disease progression (n = 71) was more common than grade ≥ 3 cardiac events (n = 19). Conclusion The 24-month cumulative incidence of grade ≥ 3 cardiac events exceeded 10% among patients with locally advanced NSCLC treated with definitive radiation. Pre-existing cardiac disease and higher mean heart dose were significantly associated with higher cardiac event rates. Caution should be used with cardiac dose to minimize risk of radiation-associated injury. However, cardiac risks should be balanced against tumor control, given the unfavorable prognosis associated with disease progression.

scholarly journals Peripartum Cardiomyopathy: An Update

2018 ◽  
Vol 14 (1) ◽  
pp. 38-41
Author(s):  
Mohammad Walidur Rahman ◽  
Manzoor Mahmood ◽  
Harisul Hoque ◽  
Fakhrul Islam Khaled ◽  
Md Abu Salim
Keyword(s):  
Cardiac Disease ◽  
Systolic Dysfunction ◽  
Viral Myocarditis ◽  
Peripartum Cardiomyopathy ◽  
Management Protocol ◽  
Life Threatening ◽  
Novel Biomarkers ◽  
Peripartum Period ◽  
Optimum Management

Peripartum cardiomyopathy is a life threatening entity of peripartum period characterized by left entricular systolic dysfunction and heart failure in absence of any known cardiac disease. Though its incidence is rising but till now its incidence, pathogenesis, optimum management protocol are not known. Oxidative stress–prolactin hypothesis , anti-angiogenic-signalling excess hypothesis, viral myocarditis and genetic predisposition are some attractive etiologic explanation but nothing is proven comprehensively. Novel biomarkers and role of new imaging modalities are being investigated. As benefit by targeted therapy like bromocriptine or pentoxifylline are inconsistent, so controlling volume status, neutralizing maladaptive neurohormonal response and treatment of complications are required.prognosis is reasonably good. The aim of this review to highlight its pathophysiology, emerging investigatios modalities, and updated management protocol.University Heart Journal Vol. 14, No. 1, Jan 2018; 38-41

Cardiac Disease in Pediatric Intensive Care

2017 ◽  
Author(s):  
Vamsi V. Yarlagadda ◽  
Ravi R. Thiagarajan
Keyword(s):  
Cardiac Output ◽  
Intensive Care ◽  
Cardiac Disease ◽  
Single Ventricle ◽  
Heart Defects ◽  
Viral Myocarditis ◽  
Pediatric Intensive Care ◽  
Low Cardiac Output Syndrome ◽  
Essential Information ◽  
Key Aspects

This chapter on cardiac disease in pediatric intensive care provides essential information on cardiovascular physiology, how to assess cardiovascular and hemodynamic status, and principles of treatment of congenital and acquired cardiac disease in children. The review of physiology includes definitions of preload, afterload, oxygen content, cardiac output, vascular resistance, blood pressure, and cardiopulmonary interactions. Formulas to calculate key parameters are provided. The authors also summarize the presentation and care of most common cyanotic and acyanotic congenital heart defects, including treatment of low cardiac output syndrome, clinical sequelae of cardiopulmonary bypass, and the key aspects of treating pre- and postoperative patients with single-ventricle lesions (e.g., hypoplastic left heart syndrome). All three stages of single-ventricle palliation are discussed, with management summaries of children undergoing the Norwood, bidirectional Glenn, and Fontan operations. Finally, the chapter includes a discussion of the clinical presentation and management of viral myocarditis and cardiomyopathy.

scholarly journals ECG Beat based Cardiac Disease Progression Monitoring for Wearables

2020 ◽  
Author(s):  
Preethi Krishnan ◽  
bashir morshed ◽  
Viswanathan Rajagopalan
Keyword(s):  
Disease Progression ◽  
Real Time ◽  
Cardiac Disease ◽  
Recent Progress ◽  
Consumer Electronics ◽  
Disease Monitoring ◽  
Real Time Monitoring ◽  
Smart Health ◽  
Fast Acting

Real-time monitoring of cardiac disease progression using consumer electronics can be of immense benefit and realizable with the recent progress of wearables. This paper proposes a fast-acting personalized smart health wearable solution for cardiac disease monitoring using Electrocardiography (ECG). <br>

Abstract P196: The Impact of MicroRNA195 on the Lkb1/AMPK Signaling Axis and Hypertrophic Cardiomyopathy

2011 ◽  
Vol 109 (suppl_1) ◽  
Author(s):  
Hao Chen ◽  
Laurel Mckee ◽  
Gustavo Untiveros ◽  
Jessica Perez ◽  
John Konhilas
Keyword(s):  
Hypertrophic Cardiomyopathy ◽  
Disease Progression ◽  
Cardiac Disease ◽  
C2c12 Cells ◽  
Acetyl Coa Carboxylase ◽  
Acetyl Coa ◽  
Ampk Signaling ◽  
Ampk Pathway ◽  
Signaling Axis ◽  
The Impact

Objectives: MicroRNAs (miRs) have been identified as chief post-transcriptional regulators of cardiac disease progression. In addition, a critical role of the adenosine monophosphate-activated kinase (AMPK) pathway in the development of myocardial hypertrophy has been revealed. Yet, regulation of the AMPK pathway by miRs in the heart has not been addressed. We hypothesized that components of the AMPK pathway are targeted by miRs and alter AMPK signaling in a mouse model of hypertrophic cardiomyopathy (HCM). Methods and results: Using real-time PCR, a candidate miR screen that included 22 miRs implicated in pathological cardiac disease and/or metabolic dysregulation was performed on hearts from 60-, 120-, and 240-day-old transgenic HCM male mice harboring an R403Q mutation in the myosin heavy gene. Among early (60 day) elevated miRs were miR-195 and -451. Both miR-195 and -451 have conserved target sites in the 3′ UTR of CAB39 (MO25), a central component of the MO25/STRAD/LKB1 complex that acts as an upstream kinase for AMPK and its subsequent activation. We further confirmed the elevation of miR-195 and -451 by Northern blotting. Next, we demonstrated specific expression and a similar distribution pattern of miR-195 and -451 in cardiomyocytes of R403Q HCM hearts by in situ hybridization. To determine whether the conserved sites in MO25 3′ UTR acted as functional targets, either the miR-195 or miR-451 target sequence was cloned into a luciferase expression vector. MiR-195 but not miR-451 suppressed luciferase activity compared to the missense sequence control vector in C2C12 cells. In addition, over-expression of miR195 in C2C12 cells knocked down MO25 expression levels and downstream AMPK signaling (phosphorylation of Acetyl CoA carboxylase). Finally, parallel changes were measured in 60 day R403Q HCM male hearts that included reduced MO25 expression and lowered phosphorlation of AMPK and Acetyl CoA carboxylase. Conclusion: Our findings indicate that miR-195 targets the LKB1/AMPK signaling axis and suggest a functional role for miR-195 elevation in R403Q HCM disease progression.

Sign in / Sign up

Export Citation Format

Share Document